Abstract
The report of the remarkable therapeutic action of glycine 1 in progressive muscular dystrophy by Thomas, Milhorat and Techner 2 has been followed by wide-spread trial of this substance in the dystrophies and in other diseases primarily involving the muscles. Beneficial effects in muscular dystrophy have been substantiated by Kostakow and Slauck, 3 Chanutin, Butt and Royster, 4 and Beard and Tripoli. 5 Boothby 6 and Remen 7 have shown that glycine is of value also in the treatment of myasthenia gravis. It would appear, however, that the treatment of muscular dystrophy has not been successful in many instances and that certain patients suffering from this disease do not respond to glycine therapy. This is evident from the reports of Boothby, 6 Milhorat, 8 and Brand and Harris. 9 Aside from the suggestion of the latter that glycine may be effective only in certain forms of muscular dystrophy, there is
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
